CRISPR THERAPEUTICS AG Cash and Restricted Cash
CRISPR THERAPEUTICS AG (CRSP) had Cash and Restricted Cash of $344.93 million as of 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2018-05-08
- 2018-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $344.93M.
- 2017-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $242.91M.
- 2017-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $292.02M.
- 2016-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $318.67M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2018-03-31 | $344.93M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $242.91M 10-Q · filed 2018-05-08 |
| 2017-03-31 | $292.02M 10-Q · filed 2018-05-08 |
| 2016-12-31 | $318.67M 10-Q · filed 2018-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |